Myeloma

**China’s CAR-T Therapy Brings Complete Remission for Primary Refractory Multiple Myeloma Patient**

**China’s CAR-T Therapy Brings Complete Remission for Primary Refractory Multiple Myeloma Patient** #MultipleMyeloma #CARTtherapy #BloodCancer #CompleteRemission #CART       Multiple Myeloma (MM) is a malignant blood disorder characterized by abnormal proliferation of plasma cells, which causes damage to vital organs. Patients with high-risk cytogenetic abnormalities like 17p deletion, t(4;14) translocation, and t(14;16) translocation face an even worse prognosis. Read More

October 3rd,2024 Myeloma

BCMA CAR-T Therapy Paves New Path for Treating High-Risk Multiple Myeloma

**BCMA CAR-T Therapy Paves New Path for Treating High-Risk Multiple Myeloma** Multiple Myeloma (MM) is a malignant tumor originating from plasma cells, known for its complex biology and treatment resistance, presenting significant challenges to patients’ survival. For high-risk MM, especially in cases of relapse and refractory disease after multiple lines of therapy, treatment options become Read More

September 30th,2024 Myeloma

Uncovering the Hidden Threat: How Serum Protein Electrophoresis Helps Diagnose Multiple Myeloma

**Uncovering the Hidden Threat: How Serum Protein Electrophoresis Helps Diagnose Multiple Myeloma** #MultipleMyeloma #BloodCancer #SerumProteinElectrophoresis #MM #Mprotein #monoclonalprotein #SPE As we age, it’s common to experience certain health issues—unexplained anemia, bone pain, fractures, nausea, or abnormal urine changes. Many may dismiss these symptoms as a result of aging, poor diet, or even mild illness. However, Read More

September 24th,2024 Myeloma

**Treatment for Multiple Myeloma: China’s BCMA×CD3 Bispecific Antibody Proposed for Breakthrough Therapy Designation**

**Treatment for Multiple Myeloma: China’s BCMA×CD3 Bispecific Antibody Proposed for Breakthrough Therapy Designation** #MultipleMyeloma #BCMAxCD3 #BispecificAntibody #Immunotherapy #GR1803 #NMPA #RRMM Recently, GR1803, an injectable solution developed by Genrix Bio, has been proposed for the “Breakthrough Therapy Designation” by the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA). This innovative drug targets Read More

September 6th,2024 Myeloma

China’s Fully Human BCMA CAR-T Therapy: Bringing New Hope for High-Risk Relapsed/Refractory Multiple Myeloma

China’s Fully Human BCMA CAR-T Therapy: Bringing New Hope for High-Risk Relapsed/Refractory Multiple Myeloma Multiple Myeloma (MM) is a complex and aggressive cancer originating from plasma cells, posing significant treatment challenges due to its resistance to therapy. For patients with high-risk MM, especially those who experience relapse after multiple lines of treatment, finding an effective Read More

August 29th,2024 Myeloma , CAR-T

Multiple Myeloma Solution ** Breakthroughs and Hope in Blood Cancer Treatment**

Multiple Myeloma Solution ** Breakthroughs and Hope in Blood Cancer Treatment** #MultipleMyeloma #BloodCancer #CART #HopeForPatients #CARTcelltherapy #Immunotherapy Multiple myeloma is a malignant blood cancer caused by the abnormal proliferation of plasma cells in the bone marrow, often affecting the bones, kidneys, and various organs and systems. With the advancement of modern medical technology, the understanding Read More

August 29th,2024 Myeloma

Иностранные пациенты ищут лечение: Лучшая терапия CAR-T в Китае! Первый российский пациент с множественной миеломой успешно очистил опухоль и достиг CR!

**Иностранные пациенты ищут лечение: Лучшая терапия CAR-T в Китае! Первый российский пациент с множественной миеломой успешно очистил опухоль и достиг CR!** В течение пяти лет после постановки диагноза высокорисковой множественной миеломы, господин Ф. испытывал невыносимые страдания. Несмотря на различные схемы химиотерапии и два пересадок, ему не удавалось полностью избавиться от кошмара непредсказуемых рецидивов и прогрессирования Read More

August 27th,2024 patient story , Myeloma

Breaking Barriers: Equecabtagene Autoleucel Revives Hope for International RRMM Patients – Multiple Myeloma

Breaking Barriers: Equecabtagene Autoleucel Revives Hope for International RRMM Patients – Multiple Myeloma Relapsed/refractory multiple myeloma (RRMM) presents a significant challenge worldwide, representing 13% of all blood cancers. Despite advances in treatment, many patients face poor outcomes and limited options. However, a groundbreaking CAR-T therapy, Equecabtagene Autoleucel, has recently demonstrated its life-changing potential in overcoming Read More

August 23rd,2024 Myeloma

Groundbreaking Results for Chinese CAR-T Therapy: 86% Response Rate of BCMA/GPRC5D Dual-Target Treatment Multiple myeloma

**Groundbreaking Results for Chinese CAR-T Therapy: 86% Response Rate of BCMA/GPRC5D Dual-Target Treatment** #MultipleMyeloma #ChineseCART #BCMA #GPRC5D #DualTarget #MM #RRMM Multiple myeloma (MM) is a challenging blood cancer, particularly in relapsed/refractory (R/R) cases. While therapies like proteasome inhibitors, immunomodulators, CD38 monoclonal antibodies, and stem cell transplants have improved outcomes for newly diagnosed patients, treatment-resistant forms Read More

August 21st,2024 Myeloma

Redefining Hope for High-Risk RRMM Patients Worldwide: A Singaporean Patient`s Journey to China for Groundbreaking CAR-T Therapy

Redefining Hope for High-Risk RRMM Patients Worldwide: A Singaporean Patient`s Journey to China for Groundbreaking CAR-T Therapy #MultipleMyeloma #CAR_Therapy #CancerTreatment #HRMM #MM #RRMM #CART In the fight against multiple myeloma (MM), the last few decades have seen significant advancements, yet the disease remains notoriously difficult to cure, particularly in patients with relapsed/refractory multiple myeloma (RRMM). Read More

August 20th,2024 Myeloma

22 Days from Desperation to Rebirth! Chinese CAR-T Therapy Creates Survival Miracle for Thai Multiple Myeloma Patient

22 Days from Desperation to Rebirth! Chinese CAR-T Therapy Creates Survival Miracle for Thai Multiple Myeloma Patient In July 2017, 58-year-old Ms. M was diagnosed with multiple myeloma. After receiving treatments at the best hospital in Thailand, including PCD, DVD, bortezomib and lenalidomide, autologous hematopoietic stem cell transplantation. The disease rapidly relapsed. Local doctors informed Read More

August 14th,2024 Myeloma

Overcoming Challenges and Embracing New Life! – Breakthrough Progress of Eque-cel in the Treatment of Refractory Multiple Myeloma

### Overcoming Challenges and Embracing New Life! – Breakthrough Progress of Eque-cel in the Treatment of Refractory Multiple Myeloma In the treatment of multiple myeloma (MM), how do we find new breakthroughs for patients who have not achieved complete remission (CR) after multiple rounds of chemotherapy? Research by Chinese medical professors has provided an exciting Read More

August 8th,2024 Myeloma